Subtle Medical has received FDA clearance for SubtleSYNTH, an AI driven software solution which uses deep learning to generate synthetic STIR images from already-acquired T1 and T2 weighted contrasts.
Why we are covering this topic
- The use of AI to streamline image acquisition through synthetic imaging is a relatively new concept, however there are already a number of examples of the technology coming to market in various modalities.
- Subtle claims that its suite of imaging solutions will “redefine what’s possible for the speed and quality of MRI imaging”, and that its SubtleSYNTH solution enables the generation of STIR images with zero acquisition time.
Why it matters
- Workforce and resource challenges are the most significant concerns for healthcare providers around the world.
- Consequently, the use of AI to speed up the image acquisition process is closely aligned with providers’ priorities and will be one of the key drivers for wider adoption of the technology.
Read the full insight with a Signify Premium Insights - Healthcare IT subscription